significantGenetic finding
INSAID classification system validated for TRAPS treatment decisions
TNF Receptor-Associated Periodic Syndrome →Summary
Papa et al. (2021) demonstrated that INSAID variant classification (Groups A/B/C) combined with Eurofever criteria reliably predicts treatment needs in 226 TRAPS patients. Anti-IL-1 drugs achieved >85% complete response in Group A.
Source
Grade Bcohort
INSAID variant classification and Eurofever criteria guide optimal treatment strategy in patients with TRAPS: data from the Eurofever Registry
Papa R, Lane T, Minden K, Touitou I, Cantarini L, Cattalini M, Obici L, et al. · J Allergy Clin Immunol Pract · 2021
- •226 patients classified by INSAID: Group A (pathogenic) 56%, Group B (uncertain) 35%, Group C (benign) 9%
- •Anti-IL-1 drugs achieved >85% complete response in patients meeting Eurofever criteria
- •No patients on anti-IL-1 treatment developed AA amyloidosis
More from TNF Receptor-Associated Periodic Syndrome
significantTreatment update
Long-term CLUSTER extension confirms sustained canakinumab efficacy in TRAPS
incrementalTreatment update
Tocilizumab case reports expand treatment options for refractory TRAPS
significantNew research
French national series quantifies AA amyloidosis severity in TRAPS
incrementalepidemiology
R92Q prevalence in inflammatory disease cohorts higher than expected
ID: traps-update-1Type: genetic_findingImpact: significant